Status Epilepticus - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Status Epilepticus - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Status Epilepticus - Pipeline Review, H1 2015', provides an overview of the Status Epilepticus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Status Epilepticus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Status Epilepticus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Status Epilepticus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Status Epilepticus Overview 6
Therapeutics Development 7
Pipeline Products for Status Epilepticus - Overview 7
Pipeline Products for Status Epilepticus - Comparative Analysis 8
Status Epilepticus - Therapeutics under Development by Companies 9
Status Epilepticus - Therapeutics under Investigation by Universities/Institutes 10
Status Epilepticus - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Status Epilepticus - Products under Development by Companies 14
Status Epilepticus - Products under Investigation by Universities/Institutes 15
Status Epilepticus - Companies Involved in Therapeutics Development 16
Ligand Pharmaceuticals, Inc. 16
Sage Therapeutics 17
Status Epilepticus - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
ADD-405008 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
fosphenytoin sodium - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SAGE-217 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SAGE-547 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SAGE-689 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SGE-102 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TG-4155 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Status Epilepticus - Recent Pipeline Updates 35
Status Epilepticus - Dormant Projects 38
Status Epilepticus - Product Development Milestones 39
Featured News & Press Releases 39
Apr 04, 2013: Sage Therapeutics Presents Clinical Data On SGE-102 At 4th London-Innsbruck Colloquium On Status Epilepticus And Acute Seizures Conference 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products under Development for Status Epilepticus, H1 2015 7
Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Status Epilepticus - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 16
Status Epilepticus - Pipeline by Sage Therapeutics, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 25
Status Epilepticus Therapeutics - Recent Pipeline Updates, H1 2015 35
Status Epilepticus - Dormant Projects, H1 2015 38